Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1201 to 1215 of 1505 results for patients and public

  1. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

  2. Mental health interventions to support discharge from general inpatient hospital settings:- What interventions are cost effective in supporting people with mental health difficulties on discharge from general hospital inpatient settings?

    important for patients with dementia or delirium because early identification of difficulties might lead to long-term savings for the...

  3. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

  4. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

  5. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

  6. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

  7. Generalised anxiety disorder and panic disorder in adults: management (CG113)

    This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

  8. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  9. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

  10. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  11. Septostomy with or without amnioreduction for the treatment of twin-to-twin transfusion syndrome (IPG199)

    Evidence-based recommendations on septostomy with or without amnioreduction for treating twin-to-twin transfusion syndrome. This involves creating a small hole in the membrane between the babies to allow the amniotic fluid to move from one baby to the other, so both babies have a more equal amount of amniotic fluid.

  12. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

  13. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

  14. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .